Valeant hikes bid for Afexa; Cleveland BioLabs launches preclin cancer drug subsidiary; Mela diagnostic on path to an approval;

 @FierceBiotech: PacBio wants to offer sequencing machine users new cloud computing capabilities. Company is working with Cycle Computing. Story | Follow @FierceBiotech

 @RyanMFierce: Cancer drug shortages keep getting worse, bad trend for developers and patients. Report | Follow @RyanMFierce

 @MaureenFierce: Reading: Downsizing trend leaves pharma without the kinds of employees it needs. Story via @Pharmalot | Follow @MaureenFierce

> Valeant has bumped its bid for Afexa after a hostile suitor, Paladin Labs, offered to sweeten its own offer. Valeant says it will pay $85.4 million for Afexa in an effort aimed at adding Cold-FX to its list of marketed drugs. Story

> With up to $26 million in support from a Russian venture fund, Cleveland BioLabs is setting up a new subsidiary to develop to develop a portfolio of preclinical cancer drugs. Report

> Shares of Mela Sciences soared this morning after the company reported that regulators had alerted the biotech that its diagnostic tool for melanoma was on track to an approval. Story

> The JDFR will collaborate with iCo on a program to to investigate iCo-007 in diabetic macular edema. Release

> Amarin has submitted an NDA for AMR101. Release

Pharma News

@FiercePharma: While the EU takes more time to weigh its Cephalon deal, Teva agrees to buy out Japanese JV partner for $150M. Story | Follow @FiercePharma

> Cancer costs growing 'unsustainable,' expert panel says. Report

> Afinitor data could be 'game-changer' in breast cancer. Article

> Swiss paper totes up Novartis layoff count: 2,500. Story

Medical Device News

 @FierceMedDev: Neat! Diagnostic Development Unit Is A Star Trek-Style Sick Bay Bed via PSFK. Report | Follow @FierceMedDev

> Delcath taps Miao as CFO. Story

> Occlutech CEO scores win against St Jude-AGA Medical. Item

> Mela receives approvable letter for cancer device. Report

> Bausch + Lomb makes exec moves. News

> PENTAX launches first HD video bronchoscope. Story

Biotech IT News

> NextDocs expands to West Coast. Report

> PacBio reaches for cloud tech amid biz slump. Report

> Brain Resource scores $10M, opens SF office. News

> NIH backs tech linking trial data, patient records. Story

> Computational analysis points to potential HIV targets. Article

And Finally... Investigators have zeroed in on a prime genetic suspect to explain why 40% of asthma patients don't respond to common therapies. Story

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.